Kornimate/medical-research-clean huggingface dataset:
hbot application in erectile dysfunction

Conditions: Erectile Dysfunction; Hyperbaric Oxygen Therapy

Summary: recent studies have shown that hyperbaric oxygen therapy (hbot) can induce angiogenesis and improve impaired organ function. hbot was also recently suggested as a possible therapy for ed due to surgical injuries. however, the effect of hbot on non-surgical related ed has not been investigated to date. the objective in this study was to assess the effect of hbot on patients with ed by means of sexual function questionnaires and novel imaging techniques.

a prospective analysis of men, age 18 years or older, with a clinical diagnosis of erectile dysfunction, reporting decreased and weakened nocturnal penile tumescence of six months duration or longer. patients were treated at the treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (haux-life-support gmbh). each session consisted of 90 minutes of exposure to 100% oxygen at 2 ata with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression. sexual function efficacy of the treatment was assessed using the international index of erectile function (iief) questionnaire which was filled by all patients at baseline and within 2 weeks of the last hbot session. in addition, assessing efficacy was the global efficacy question (geq) ("did the treatment improve your erections?"), with a response of yes or no. six patients underwent two mri scans 1-2 weeks prior to and after hbot. imaging was conducted in using a 3tesla system (magnetom skyra, siemens medical solutions, , germany). the mri protocol included anatomic t1 and t2 sequences and dce. the mri dce sequence parameters are detailed in supplementary section.

Eligibility criteria:
inclusion criteria: * age 18 years or older * clinical diagnosis of erectile dysfunction * reporting decreased and weakened nocturnal penile tumescence of six months duration or longer exclusion criteria: * penile anatomical defects, * any active or history of malignancy including prostate cancer * spinal cord injury * any major psychiatric disorder uncontrolled with treatment * claustrophobia * chronic lung disease * chronic middle ear or sinus diseases.

Keywords: hbot hyperbaric oxygen dce ed erectile dysfunction
laparoscopy and covid-19 contamination

Conditions: Covid19

Summary: the aim of the study is to search the presence of the sars-cov-2 virus (covid19) in the pneumoperitoneum of patients with a positive (or suspected) covid19 status during a routine laparoscopy.


Eligibility criteria:
inclusion criteria: * patient of legal age * indication for laparoscopy * positive (past or current) or suspected covid19 status (cough, fever, suggestive radiological images, etc.) * lack of opposition to participating in the study exclusion criteria: * patient under legal protection * covid19 status negative, (former or current) and not suspected * patient unable to object * patient with no social security care

Keywords: laparoscopy pneumoperitoneum
managing pain and cognitions in older adults with mild cognitive impairment or memory related problems and chronic pain

Conditions: Chronic Pain; Mild Cognitive Impairment; Older Adults; Physical Activity

Summary: we aim to conduct a pilot randomized controlled trial comparing 2 symptom management programs for older adults with self-reported memory problems and chronic pain, active brains 1 and active brains 2. we will assess how each program may help in improving coping with pain and coping with cognitive functioning. we will explore feasibility, acceptability, and credibility and within group changes in physical, emotional and cognitive functioning.

we aim to conduct a pilot randomized controlled trial comparing 2 symptom management programs for older adults with self-reported memory problems and chronic pain: active brains 1 active brains 2. we will assess how each program may help in improving coping with pain and coping with cognitive functioning. we will explore feasibility, acceptability, and credibility and within group changes in physical, emotional and cognitive functioning. each group meets for 8 90 minute sessions over a secure video platform. each group has 5-8 participants. participants receive a treatment manual. there are 2 assessment points: baseline, and post program. assessments involve questionnaires, a walk test, and objective step count with actigraphs for 1 week.

Eligibility criteria:
inclusion criteria: * male and female patients, age 60 years or older * have nonmalignant chronic pain for more than 3 months * has mci or subjective memory related problems * able to perform a 6-minute walk test at an accelerated pace * owns a smartphone with bluetooth 4.0 * willingness and ability to participate in the active brains intervention and to comply with the requirements of the study protocol (including weekly sessions and fitbit use) * free of concurrent psychotropic or pain medication for at least 2 weeks prior to initiation of treatment, or stable on current psychotropic or pain medication for a minimum of 6 weeks and willing to maintain a stable dose * cleared by a medical doctor for study participation * leads a sedentary lifestyle exclusion criteria: * diagnosed with medical illness expected to worsen in the next 6 months * serious mental illness or instability for which hospitalization may be likely in the next 6 months * current suicidal ideation reported on self-report * lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder, or substance dependence * current substance use disorder, within the past 6 months * practice of yoga/meditation, or other mind-body techniques that elicit the relaxation response, once per week for 45 minutes or more within the last 3 months or less * regular use of fitbit in the last 3 months * engagement in regular intensive physical exercise for \>30 minute daily * unable to walk without use of assistance (e.g., wheelchair, walker)

Keywords: chronic pain mild cognitive impairment older adults physical activity memory related problems
single application of desensitizing pastes as dentin sensitivity treatment

Conditions: Dentine Hypersensitivity

Summary: the aim of this study was to evaluate the efficacy of three desensitizing toothpastes for immediate and intermediate-term relief of cdh, when compared with a control toothpaste. one hundred and thirty-eight hypersensitive teeth were diagnosed and randomized into four groups according to the therapeutic agent of each desensitizing cream tested: 1) strontium acetate and calcium carbonate, 2) calcium carbonate and arginine 8%, 3) calcium phosphate nanoparticles and 4) a control toothpaste. the desensitizing creams were applied according to the manufacturer's instructions. cervical dentin hypersensitivity was assessed at baseline, immediately, 24 hours and 30 days after the treatment. cold and evaporative tests were used to assess the sensitivity level.


Eligibility criteria:
inclusion criteria: * subjects 18 years or older * in good general and oral health; have complaint of cdh in teeth distributed in all 4 quadrants * not making use of desensitizing agents * not having undergone periodontal treatment over the past 3 months * respond to evaporative stimulus with a score ≥ 1.5 cm on vas exclusion criteria: * patients who presented restorations and caries near the exposed dentin of the hypersensitive teeth * who made frequent use of painkillers, anti-inflammatory and antidepressants drugs
lynch syndrome can be diagnosed just from somatic mismatch repair mutation

Conditions: Cancer Gene Mutation; Lynch Syndrome; Endometrial Cancer; Somatic Mutation

Summary: the objective of the study is the provide proof of high correlation between somatic and germline mismatch repair instability. this correlation is specifically researched in an area where patients have less access to cancer education and genetic testing for various reasons such as lack of insurance and general accessibility. the study concentrates on early diagnosis of lynch syndrome. lynch syndrome is usually diagnosed from a blood test resulting in a mutation of one of the mismatch repair genes. those are mlh1, msh2, msh 6, pms2. a mutation in one of these genes creates a mismatch repair instability,hence higher incidence of cancers in specific organ groups. amongst these organs are the uterus, ovaries, upper genitourinary system, pancreas and gi system. the most common endometrial carcinoma which is found in lynch syndrome is of endometrioid histology. most patients with known germline mismatch repair instability, have the same somatic mutation. our study is looking into correlating somatic mutation to germline mutation. by doing so, patients diagnosed with somatic mismatch repair instability will be also diagnosed with lynch syndrome without germline genetic testing. screening programs will be utilized earlier and preventive procedures offered. due to less access to educational programs, genetic counseling and testing in underserved areas, patients are sometimes lost to follow up. our study seeks to prove high correlation between somatic and germline mutations and by doing so, patient will be diagnosed with lynch syndrome straight after endometrial cancer staging. as a result, increased compliance will be expected and patients will be offered the recommended preventative surgeries and screening protocols.


Eligibility criteria:
inclusion criteria: underserved areas. diagnosis of endometrial endometrioid carcinoma. low socioeconomic status. positive mismatch repair staining. all races. all ages. all cancer grades. all cancer stages . exclusion criteria: diagnosis of type 2 endometrial carcinoma. cancer diagnosis other than endometrial. no mismatch repair genes mutation. high socioeconomic status.
lenvatinib plus deb-tace with/without folfox-haic for large hcc with pvtt

Conditions: Hepatocellular Carcinoma Non-resectable

Summary: this multicenter retrospective study evaluated consecutive patients with large hcc and pvtt who received lenvatinib plus deb-tace with/without folfox-haic between july 2019 and june 2021. tumor response, time to progression (ttp), overall survival (os), and treatment-related adverse events (traes) were compared between the two groups.

consecutive patients with large hcc and pvtt treated with lenvatinib plus drug-eluting bead transarterial chemoembolization (deb-tace) and hepatic arterial infusion chemotherapy (haic) with oxaliplatin, fluorouracil and leucovorin (len+deb-tace+haic) or lenvatinib plus deb-tace (len+deb-tace) from july 2019 to june 2021 were screened. tumor response was evaluated according to modified response evaluation criteria in solid tumors (mrecist). clinical outcomes, including tumor response, ttp, os, and traes were compared between the two groups.

Eligibility criteria:
inclusion criteria: * a confirmed diagnosis of hcc * the largest intrahepatic lesion \>7 cm * presence of major pvtt on imaging * eastern cooperative oncology group performance status ≤1 * child-pugh class a/b * adequate hematologic and organ function, with leukocyte count 3.0 109/l, neutrophil count 1.5 109/l, platelet count 75 109/l, hemoglobin 85 g/l, alanine transaminase and aspartate transaminase 5 upper limit of the normal, creatinine clearance rate 1.5 upper limit of the normal, and prothrombin time prolongation \<4 s exclusion criteria: * incomplete medical records * central nervous system involvement * previous treatment with transarterial embolization, tace, haic, radiotherapy, or systemic therapy * history of malignancies other than hcc * history of organ transplantation * severe cardiac, pulmonary or renal dysfunction

Keywords: hepatocellular carcinoma lenvatinib transarterial chemoembolization drug-eluting bead hepatic arterial infusion chemotherapy portal vein tumor thrombosis
ticin pilot study: sirolimus-eluting balloon for stabilization and regression of non-obstructive coronary plaques.

Conditions: Coronary Arterial Disease (CAD); Vulnerable Coronary Plaques; Multivessel Coronary Artery Disease; Coronary Vessel; Acute Coronary Syndromes (ACS)

Summary: the goal of this pilot clinical trial is to evaluate the use of the selution slr sirolimus-eluting balloon, in addition to guideline-directed medical therapy (gdmt), for the preventive treatment of non-flow-limiting vulnerable coronary lesions, compared to gdmt alone, in adult patients with multivessel coronary artery disease and a recent acute coronary syndrome (within 90 days). the main research question is: does the use of the selution slr sirolimus-eluting balloon in combination with gdmt reduce the progression and vulnerability of non-flow-limiting vulnerable coronary plaques? participants will undergo * pci procedure with baseline ivus-nirs assessment * follow-up coronary angiography at 6 months with ivus-nirs assessment * clinical follow-up at 3, 6, and 24 months after study enrollment


Eligibility criteria:
inclusion criteria: potential subjects must fulfill all following inclusion criteria: 1. multivessel coronary artery disease with acs within 90 days prior to inclusion and successful interventional treatment of the culprit lesion 2. presence of ≥ 2 de novo non-culprit lesion without hemodynamic relevance in two different coronary vessels (demonstrated either by wire-based or angiography-based coronary physiology) and with maxlcbi4mm ≥ 325 at baseline ivus-nirs 3. age ≥ 18 years 4. written informed consent exclusion criteria: patients are not eligible if any of the following applies: 1. non culprit lesion involving the left main and/or ostial left coronary artery, ostial left circumflex artery or ostial right coronary artery; 2. non-culprit lesion in a previously stented segment (i.e. within 15 mm from the previously implanted stent); 3. non-culprit lesion involving small vessel (\<3.0 mm) deemed not suitable to pci, 4. non-culprit lesion located in a bypass graft or in a grafted vessel; 5. severe renal impairment (egfr\<15ml/min/1.73m2) or patient on dialysis treatment; 6. known pregnancy r breast-feeding patients; 7. life expectancy \<2 year due to other severe non-cardiac disease; 8. legally incompetent to provide informed consent; 9. partecipation in another clinical study with an investigational product

Keywords: coronary arterial disease (cad) vulnerable coronary plaques multivessel coronary artery disease coronary vessel acute coronary syndromes (acs) non-flow limiting vulnerable coronary plaques sirolimus-eluting deb deb selution slr guidelines-directed medical therapies (gdmt) ivus-nirs maxlcbi4mm maxlcbi4mm≥325 lipid core burden index (lcbi)
a randomized, double masked, clinical study of subjects with dry eye syndrome

Conditions: Dry Eye Syndromes

Summary: the objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of adx-102 ophthalmic solutions and adx-102 ophthalmic lipid solution in subjects with dry eye syndrome.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age of either gender and any race; * have a reported history of dry eye for at least 6 months prior to visit 1; * have a history of use or desire to use eye drops for dry eye symptoms within 6 months of visit 1; exclusion criteria: * have any clinically significant slit lamp findings at visit 1 that may include active blepharitis, meibomian gland dysfunction (mgd), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters; * be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at visit 1; * have worn contact lenses within 7 days of visit 1 or anticipate using contact lenses during the study; * have previously had laser-assisted in situ keratomileusis (lasik) surgery within the last 12 months; * have used cyclosporine 0.05% or lifitegrast 5.0% ophthalmic solution within 45 days of visit 1; * have any planned ocular and/or lid surgeries over the study period or any ocular surgery within the last 6 months; * be using or anticipate using temporary punctal plugs during the study that have not been stable within 30 days of visit 1;

Keywords: aldeyra
how improvement in control of diabetes influences the production of a hormone produced in the gut which improves the release and action of insulin.

Conditions: Type 2 Diabetes Mellitus

Summary: the study is aimed at type 2 diabetics who are taking metformin, but whose diabetes remains poorly controlled. there are two additional medications already in use, glimepiride and sitagliptin will be compared to assess levels of improvement in diabetes control.


Eligibility criteria:
inclusion criteria: * diabetes mellitus * currently on metformin but poor glycaemic control, exclusion criteria: * under 18 years of age

Keywords: diabetes mellitus glp1 dpp4
pathophysiological implications of the incretin hormones in patients with liver disease with and without diabetes

Conditions: Non Alcoholic Fatty Liver Disease; Type 2 Diabetes; Liver Cirrhosis

Summary: the main objective of this study is to analyze the pathophysiological implications of glucagon and the incretin hormones in patients with liver disease (non alcoholic fatty liver disease (nafld) or cirrhosis) with and without diabetes compared with healthy controls. the present study will contribute significantly to the understanding of the pathophysiology of liver disease and glucose metabolism. the final goal is that the results could pave the way for new treatment modalities for patients with liver disease.

comparison of of insulin secretion (area under the curve (auc)) during the experimental days. furthermore a comparison of gip, glp1 and glucagon responses as well as plasma glucose levels.

Eligibility criteria:
i) group 1: nafld patients with normal glucose tolerance inclusion criteria * nafld verified by a liver biopsy * caucasian \>18 years of age * negative islet cell (ica) and glutamic acid decarboxylase 65 (gad65) autoantibodies * normal 75-g ogtt as specified in the who criteria * normal haemoglobin and blood pressure (bp) * written informed consent ii) group 2: nafld patients with type 2 diabetes inclusion criteria * nafld verified by liver biopsy * t2dm according to the who criteria * caucasian \>18 years of age * negative ica and gad65, normal haemoglobin, normal bp * written informed consent iii) group 3: nafld patients without type 2 diabetes inclusion criteria * nafld verified by liver biopsy * caucasian \>18 years of age * normal 75-g ogtt * negative ica and gad65-autoantibodies * normal haemoglobin and bp * written informed consent iv) group 4: cirrhosis with or without type 2 diabetes inclusion criteria * liver cirrhosis verified by liver biopsy * caucasian \> 18 years of age * negative ica and gad65-autoantibodies * normal haemoglobin and bp * written informed consent v) group 5: healthy controls inclusion criteria * caucasian \>18 years of age * normal 75-g ogtt according to the who criteria * negative ica and gad65-autoantibodies * normal haemoglobin and bp * written informed consent exclusion criteria (all groups) * other known liver disease - viral hepatitis, hereditary haemochromatosis, autoimmune liver disease, alpha-1 trypsin deficiency, wilson disease, drug induced liver injury (dili) * treatment with medications that cannot be discontinued for 12 hours * unwillingness to participate in protocols * pregnancy or lactation

Keywords: nafld incretin hormones
effects of preoperative inspiratory muscle training (imt) in obese women undergoing open bariatric surgery

Conditions: Preoperative Inspiratory Muscular Training; Bariatric Surgery; Chest Physiotherapy; Postoperative Pulmonary Complications; Obesity

Summary: objective: to determine whether preoperative inspiratory muscle training (imt) is able to attenuate the impact of surgical trauma on the respiratory muscle strength, in the lung volumes and diaphragmatic excursion in obese women undergoing open bariatric surgery. therefore, the hypothesis of the present study was that preoperative imt is able to attenuate the negative effects of surgical trauma on the respiratory muscle strength, in the lung volumes and diaphragmatic excursion, thus reducing the risk of ppc, in obese patients undergoing open bariatric surgery. design: randomized controlled trial. setting: meridional hospital, cariacica/es, brazil. subjects: thirty-two obese women undergoing elective open bariatric surgery were randomly assigned to receive preoperative inspiratory muscle training (imt group) or usual care (control group). main measures: respiratory muscle strength (maximal inspiratory pressure - mip and maximal expiratory pressure - mep), lung volumes and diaphragmatic excursion.


Eligibility criteria:
inclusion criteria: * female, * over 18 years of age, * no smoking or respiratory disease. exclusion criteria: * patients who refused to participate in the steps of the research protocol, * patients with a history of prior abdominal surgery, * patients who were unable to understand and perform the tests properly * patients who refused to sign the informed consent term.
recombinant human interferon a-2b gel for hpv-16 and/ or hpv-18 gynecological infections

Conditions: Cervical HPV-16 and / or HPV-18 Infection

Summary: to assess the efficacy and safety of recombinant human interferon α-2b gel (yallaferon®) for the treatment of patients with cervical hpv-16 and/or hpv-18 infections; to analyze the hpv type infections and clinical negative conversion.

100 patients with positive hpv-16 and hpv-18 infection are randomized into interferon gel group and control group at ratio of 1:1 (50 patients in treatment group and 50 patients in control group). the patients in treatment group received 1g recombinant human α-2b interferon gel every other day for consecutive 6-10 courses of treatment, whereas no treatment was conducted in control group.

Eligibility criteria:
inclusion criteria: * age 25 to 65 years of age with the sex life of female patients; * hpv dna typing test for hpv-16 and/ or hpv-18 positive in 1 month. exclusion criteria: * patients with cervical intraepithelial neoplasia ⅱ / ⅲ, cervical cancer; * associated with fungal vaginitis, trichomonas vaginitis, hiv positive patients; * associated with acute, severe bacterial or viral infection; * autoimmune diseases; * within 3 months before screening patients used corticosteroids, immunosuppressants or other antiviral drugs; * allergies or allergy to the drug known ingredients; * history of suffering cns diseases, epilepsy and/or psychological disorder; * pregnant and lactating women; * the researchers do not consider it appropriate clinical trials.